HomeCompareRECEF vs PLD

RECEF vs PLD: Dividend Comparison 2026

RECEF yields 909.09% · PLD yields 3.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RECEF wins by $8252642.30M in total portfolio value
10 years
RECEF
RECEF
● Live price
909.09%
Share price
$0.22
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8252648.21M
Annual income
$6,784,560,004,057.53
Full RECEF calculator →
PLD
PLD
● Live price
3.10%
Share price
$132.18
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.91M
Annual income
$4,750,725.19
Full PLD calculator →

Portfolio growth — RECEF vs PLD

📍 RECEF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRECEFPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RECEF + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RECEF pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RECEF
Annual income on $10K today (after 15% tax)
$77,272.73/yr
After 10yr DRIP, annual income (after tax)
$5,766,876,003,448.90/yr
PLD
Annual income on $10K today (after 15% tax)
$263.66/yr
After 10yr DRIP, annual income (after tax)
$4,038,116.41/yr
At 15% tax rate, RECEF beats the other by $5,766,871,965,332.49/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RECEF + PLD for your $10,000?

RECEF: 50%PLD: 50%
100% PLD50/50100% RECEF
Portfolio after 10yr
$4126327.06M
Annual income
$3,392,282,377,391.36/yr
Blended yield
82.21%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

RECEF
No analyst data
Altman Z
-148.3
Piotroski
1/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+2.9% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RECEF buys
0
PLD buys
0
No recent congressional trades found for RECEF or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRECEFPLD
Forward yield909.09%3.10%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$8252648.21M$5.91M
Annual income after 10y$6,784,560,004,057.53$4,750,725.19
Total dividends collected$8138900.96M$5.78M
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: RECEF vs PLD ($10,000, DRIP)

YearRECEF PortfolioRECEF Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$101,609$90,909.09$11,241$540.96+$90.4KRECEF
2$972,011$863,288.79$13,019$991.13+$959.0KRECEF
3$8,758,157$7,718,105.75$15,801$1,870.97+$8.74MRECEF
4$74,364,546$64,993,317.91$20,609$3,701.21+$74.34MRECEF
5$595,318,755$515,748,691.06$29,919$7,867.97+$595.29MRECEF
6$4,495,664,203$3,858,673,134.79$50,631$18,617.74+$4495.61MRECEF
7$32,043,550,537$27,233,189,840.42$105,528$51,352.20+$32043.45MRECEF
8$215,696,715,677$181,410,116,602.38$287,364$174,449.42+$215696.43MRECEF
9$1,372,045,052,584$1,141,249,566,809.58$1,081,760$774,280.77+$1372043.97MRECEF
10$8,252,648,210,323$6,784,560,004,057.53$5,908,209$4,750,725.19+$8252642.30MRECEF

RECEF vs PLD: Complete Analysis 2026

RECEFStock

Recce Pharmaceuticals Ltd, a biotechnology company, engages in the research, development, and commercialization of synthetic anti–infectives in Australia, the United States, and the United Kingdom. The company's lead candidate is RECCE 327 to treat blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. It also develops RECCE 529, a synthetic anti-infective for viral infections; and RECCE 435, a synthetic polymer anti-infective. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia.

Full RECEF Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this RECEF vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RECEF vs SCHDRECEF vs JEPIRECEF vs ORECEF vs KORECEF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.